Proactive Investors - Run By Investors For Investors

Breakfast News - Angle, ReNeuron, Cloudbuy, Evgen Pharma and others

Breakfast News - Angle, ReNeuron, Cloudbuy, Evgen Pharma and others

Dish of the day

No Joiners Today

Off the menu   

Datatec (LON:DTC) is leaving AIM but Johannesburg listing remains live.

What’s cooking in the IPO kitchen?


Erris Resources PLC—a mineral exploration and development company currently focused on two geographic areas. Offer TBC, expected 21 December 2017

CIP Merchant Capital—Closed ended investment Company. Sector focus oil & gas, healthcare, pharma, and real estate. Offer TBA. Due 21 Dec

Panthera Resources— The Company was established to act as a holding company for Indo Gold Limited, an unlisted Australian registered company. The Company aims to explore and develop gold assets in India and West Africa. Offer TBC, expected 20 Dec

Sumo Group—one of the UK's largest independent developers of AAA-rated video games providing both turnkey and co-development solutions, including initial concept and pre-production . Offer TBC. Due late Dec

Pelatro—provider of proprietary software solutions to enterprise-level customers for various aspects of precision marketing for use in B2C applications. Offer TBC, expected 19 December 2017

Fusion Antibodies—contract research organisation providing services to biopharmaceutical and diagnostics companies that are involved in the development of antibodies for both therapeutic drug and diagnostic applications.  Offer TBA. Due Mid Dec.

Sirius Petroleum—RTO. Becoming an operating company in the Ororo Field in Nigeria. Raising £7.2m/ Mkt Cap £35.6m.  Due 19 Dec.

Bushveld Minerals—RTO of Bushveld Vametco and therefore 78.8% of Strategic Minerals Corporation, the intermediate holding company that owns a 75 per cent. interest in the Vametco Vanadium Mine.

Range Resources— oil and gas company listed on the ASX plans to admit to AIM on 13 Dec with mkt cap of £17.4m. Acquiring Range Resources Drilling Services Limited, an oil services business based in Trinidad & Tobago  with extensive drilling capabilities. 

Eqtec—Company with access to a proprietary advanced gasification technology used in industrial size power plants to convert waste into synthetic gas to generate electricity.  Raising £1.6m. Mkt Cap £8.7m. Due 21 Dec.

Volex VLX.L—The global provider of cable assemblies is proposing to move from the main market to AIM on 19 January. £71m market cap. FYMar18E rev £241.5m and £7.19m PBT

Miriad Advertising—Global video advertising company incorporated in 2015 and is engaged in the development of native in-video advertising. 2016 rev £0.7m and £7.3m operating loss. Offer TBA. Expected 19 Dec.

OnTheMarket—Intention to float on AIM to raise c.£50m which will be used to fund the growth of the portal, already the third biggest UK residential property portal provider. Expected valuation £200m to £250m.

Main Market Specialist Fund Segment

Sure Ventures –Raising  up to £50m at £1. Focus on FinTech, IoT and Augmented/Virtual Reality. Due 22 Dec.

Main Market Standard Listing

Shefa Yamin minerals company focused on the exploration for precious stones in Northern Israel. Net Proceeds will be used to advance the Company's mining project. Offer TBA.

Main Market Premium Listing

GEMS Education—report by Reuters that the private schools group is seeking a $4.5bn to $5bn London float in 2018. FYAug17 rev $926.2m and adjusted EBITDA $261.6m.

Greensphere Capital -$500m raise.  Aims to provide Shareholders with an attractive yield from a portfolio of sustainable infrastructure assets diversified by geographies and sectors and to realise long-term growth  capital value.  Due 20 Dec

Vivo Energy—The Africa-focused company, which operates around 1,800 Shell forecourts across 16 countries  reported by City A.M. to be preparing for a London float next year

Aberdeen Standard European Logistics Income—Investment Trust targeting £250m raise. Investing in a high quality portfolio of European logistics assets. Due 15 Dec.

Aviva Investors Secure Income REIT  - Targeting £200m raise. Will invest in a diversified portfolio of high quality, long-lease commercial real estate assets located within the UK and leased to predominantly investment grade tenants. Due 15 Dec.

Breakfast buffet

Vela Technologies (LON:VELA) 0.55p £3.97m

The investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to announce that the Company has entered into a conditional agreement to invest £200,589 to acquire a minority equity stake in BlockchainK2 Corp. This is conditional on the investee Company raising  a total of C$2m.

BlockchainK2 is a cryptocurrency and blockchain platform that offers mining exposure and proprietary software as a service (SAAS) blockchain solutions with leading industry partners. The Proposed Investment will be funded from Vela's existing cash resources.

  Touchstone Exploration (LON:TXP) 12p £12.38m

Intends to complete a £3m private placement at 11.5p.

“The Company previously announced that it plans to drill four wells on its Coora 2 and WD-8 properties commencing in January 2018. The Company intends to use the net proceeds from the Private Placement of approximately £2.7m (approximately C$4.6m) to finance the expansion of Touchstone's 2018 drilling programme from four wells to ten wells. The additional wells are expected to be drilled on the Company's Coora 1, WD-4, WD-8 and South Palo Seco properties. In conjunction with the enlarged drilling programme, Touchstone's Board of Directors also approved a 24 well recompletion programme in 2018.”

ReNeuron (LON:RENE) 1.85p £58.55m

The “UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has established an office in Boston, MA, USA. This office will initially house the Company's US-based clinical, medical and scientific communications staff and reflects the Company's focus on clinical development activities in the US across its therapeutic programmes. 

During 2018, the Company plans to have three placebo-controlled Phase IIb clinical trials running with its CTX and hRPC cell therapy candidates, in stroke disability and retinal diseases. All of these studies will be conducted in clinical trial centres across the US.”

Bluejay Mining (LON:JAY) 22.5p £179.19m

Completion of maiden 2017 field work programme at the 100% owned Disko Nickel, Copper, Cobalt & Platinum Project in West Greenland. Surface sampling confirms working sulphide system with initial chemical assays in oxidised surface material returning 2.02% Nickel, 0.8% Copper, 0.2% Cobalt

•    Handheld XRF sampling on fresh, polished material returned values averaging between 4.6%-9.3% Nickel & 1.5 - 2.8% Copper

• Results from 2017 exploration work together with historical data will continue to be assessed in the coming months to refine targets for future exploration work

• Standalone exploration programme planned for 2018 to advance project understanding in  recently enlarged licence area, now comprising 970km2

Tiziana Life Sciences (LON:TILS) 145p £186.17m

The “clinical stage biotechnology company developing targeted drugs for cancer and inflammatory diseases, today announces that the independent data monitor committee (IDMC) completed interim analysis of the safety and pharmacokinetic data from the first six patients and concluded that treatment with Milciclib was safe and well-tolerated with no drug-related serious adverse events (SAEs) in patients with unresectable or metastatic  Hepatocellular Carcinoma (HCC).  The IDMC recommended continuing with the trial.”

As a next step, a Phase 2b trial to evaluate safety and clinical activity of Milciclib in combination with sorafenib (NexavarÒ; Bayer Germany) in HCC is expected to start in Q2, 2018.

Cloudbuy (LON:CBUY) 2.62p £3.42m

Roberto Sella, who has already provided significant financial support to the Company, has agreed to subscribe for up to a further £3.4m nominal value loan notes similar to those issued by the Company in April 2016. The Directors currently believe that the initial issue of £1.7m nominal value New CLS will be sufficient to take the Company to profitability. Cloudbuy has exited numerous markets where revenue traction was slow and has also  focussed resource on the PHBChoices UK care marketplace through its customer NHS Shared Business Services Limited.

FYDec17E rev £1.8m and pre-tax loss £2.3m.


Angle (LON:AGL) 47.5p £55.6m

The “liquid biopsy company, is delighted to announce that the University of Southern California (USC) Norris Comprehensive Cancer Center yesterday presented results of extensive work with ANGLE's ParsortixTM system at the San Antonio Breast Cancer Symposium (SABCS) detailing how the system can be used to obtain comparable gene expression information from a simple blood test in place of an invasive solid tissue biopsy of a metastatic site. “ ANGLE is working towards an FDA clearance of the Parsortix system in metastatic breast cancer with the required analytical and clinical studies targeted for completion by 30 June 2018.

Evgen Pharma (LON:EVG) 16.63p £12.32m

Conditional £2.3m placing at 12 p and HY Sep 17 results. £1.7m loss with cash and short term investments of £2.2m.

Good progress in the Company's Phase II metastatic breast cancer clinical trial ('STEM') of SFX-01, the Company's lead product. Seven sites open for recruitment across UK, Belgium and Spain. On track to report in second half of 2018 with interim read-out in H1 2018

Phase II subarachnoid haemorrhage stroke trial ('SAS') of SFX-01 on track to report around the end of 2018

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here

Important Risk Warnings and Disclaimers 

This report is published by Beaufort Securities Ltd ("Beaufort Securities"). Beaufort Securities Ltd is Authorised and Regulated by the Financial Conduct Authority and is a Member of the London Stock Exchange. 


This document is not an offer to buy or sell any security or currency. This document does not provide you with individually tailored investment advice. It has been prepared without regard to the your financial circumstances and objectives The appropriateness of a particular investment or currency will depend on your individual circumstances and objectives. The investments and shares referred to in this document may not be suitable for you. 

This research is non-independent and is classified as a Marketing Communication under FCA rules. As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition on dealing ahead of the dissemination of investment research in COBS 12.2.5. However Beaufort Securities has adopted internal procedures which prohibit analysts from dealing ahead of non-independent research, except for legitimate market making and fulfilling clients' unsolicited orders. 

By receiving this document, you will not be deemed a client or provided with the protections afforded to clients of Beaufort Securities. When distributing this document, Beaufort Securities is not acting for you and will not be responsible for providing advice to you in relation to this document. Accordingly, Beaufort Securities will not be responsible to you for providing the protections afforded to its clients. 

Beaufort Securities may effect transactions in shares mentioned herein and may take proprietary trading positions in those shares, and may receive remuneration for the publication of its research and for other services. Beaufort Securities may be a shareholder in any of the companies mentioned in this report. Accordingly, this document may not be considered as objective or impartial. Additionally, information may be available to Beaufort Securities or the Group, which is not reflected in this material. The remuneration of the author of this report is not tied to the recommendations on any shares mentioned nor to the any transactions undertaken by Beaufort Securities or any affiliate company. Further information on Beaufort Securities' policy regarding potential conflicts of interest in the context of investment research and Beaufort Securities' policy on disclosure and conflicts in general are available on request. Please refer to 

Past performance is not a guarantee of future performance. Investments may go down in value as well as up and you may not get back the full amount invested. The listing requirements for securities listed on AIM or the ICAP Securities & Derivatives Exchange are less demanding and trading in them may be less liquid than main markets. This may make it more difficult to buy and sell these securities. 


This document includes certain statements, estimates, and projections with respect to the anticipated future performance of securities listed on stock exchanges and as to the market for these shares. Such statements, estimates, and projections are based on information that we consider reliable and may reflect various assumptions made concerning anticipated economic developments, which have not been independently verified and may or may not prove correct. No representation or warranty is made as to the accuracy of such statements, estimates, and projections or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only and may change without notice. Other third parties may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views, and analytical methods of the analysts who prepared them. This report has not been disclosed to any of the companies mentioned herein prior to its publication. 

This document is based on information Beaufort Securities has received from publicly available reports and industry sources. Beaufort Securities may not have verified all of this information with third parties. Neither Beaufort Securities nor its advisors, directors or employees can guarantee the accuracy, reasonableness or completeness of the information received from any sources consulted for this publication, and neither Beaufort Securities nor its advisors, directors or employees accepts any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by the applicable law). You should not rely on this document and should not use it substitution for the exercise of the independent judgment of yourself or your adviser. 

The information contained in this document is confidential and is solely for use of those persons to whom it is addressed and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Other persons who receive this document should not rely on it. Beaufort Securities, its directors, officers and employees may have positions in the securities mentioned herein.


© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use